Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Weber, Britta ^a   Meldgaard, Peter ^a   Hager, Henrik ^a   Wu, Lin ^b   Wei, Wen ^b   Tsai, Julie ^b   Khalil, Azza ^a   Nexo, Ebba ^a   Sorensen, Boe S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

EGFR (Epidermal growth factor receptor); Erlotinib; Lung cancer; Plasma DNA

Indexed keywords

ERLOTINIB; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; CHLAMYDIA MULTIPLEX PCR ASSAY; CONTROLLED STUDY; DNA ISOLATION; ETHNICITY; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; RELIABILITY; VERY ELDERLY; BIOPSY; BLOOD; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899956118     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-294     Document Type: Article

References (13)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938, 15118073.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500. 10.1126/science.1099314, 15118125.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311. 10.1073/pnas.0405220101, 516528, 15329413.
4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181. 10.1038/nrc2088, 17318210.
5. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, Duan J, Yang L, Wu M, Liang Z, Wang Y, Kang X, Wang J. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012, 30(25):3077-3083. 10.1200/JCO.2011.39.3744, 22826274.
6. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27(16):2653-2659. 10.1200/JCO.2008.17.3930, 19414683.
7. Brevet M, Johnson ML, Azzoli CG, Ladanyi M. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung cancer 2011, 73(1):96-102. 10.1016/j.lungcan.2010.10.014, 3282180, 21130517.
8. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012, 7(1):115-121. 10.1097/JTO.0b013e3182307f98, 21900837.
9. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006, 12(13):3915-3921. 10.1158/1078-0432.CCR-05-2324, 16818687.
10. Yam I, Lam DC, Chan K, Chung-Man Ho J, Ip M, Lam WK, Chan TK, Chan V. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients. J Thorac Oncol 2012, 7(7):1131-1140. 10.1097/JTO.0b013e3182558198, 22610259.
11. Zhao X, Han RB, Zhao J, Wang J, Yang F, Zhong W, Zhang L, Li LY, Wang MZ. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013, 85(2):119-125. 10.1159/000338790, 22797485.
12. Hu C, Liu X, Chen Y, Sun X, Gong Y, Geng M, Bi L. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 2012, 28(5):1815-1821.
13. Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Koo JH, Lee HC, Lee OJ. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Canc 2011, 12(6):380-386.